Gilead Sciences (GILD)
(Delayed Data from NSDQ)
$113.18 USD
+0.89 (0.79%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $113.18 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
B Value A Growth B Momentum A VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
GILD 113.18 +0.89(0.79%)
Will GILD be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for GILD based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for GILD
Gilead Sciences (GILD) Expected to Beat Earnings Estimates: Should You Buy?
Is Most-Watched Stock Gilead Sciences, Inc. (GILD) Worth Betting on Now?
GILD: What are Zacks experts saying now?
Zacks Private Portfolio Services
Gilead Sciences (GILD) Stock Dips While Market Gains: Key Facts
Top Research Reports for NVIDIA, Netflix & Goldman Sachs
Here's Why Gilead Sciences (GILD) is a Strong Value Stock
Other News for GILD
Notable healthcare headlines for the week: Trump’s ultimatum to big pharma, Novo Nordisk, UnitedHealth and Moderna in focus
Earnings week ahead: AMD, PLTR, PFE, DIS, O, ET, SHOP, GILD, MCD, CAT, VTRS, BP, UBER, CGC, and more
ClearBridge Value Portfolios Q2 2025 Commentary
Market Voices: Trump vs. Big Pharma, Swiss tariffs, tariff legality
Gilead Sciences (GILD) Linked to False Rumors Affecting Pheton Holdings